Clinical Trial Update: Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) [Phase 1]

View source ↗

Summary

Phase 1 safety study of recombinant human acid sphingomyelinase enzyme replacement therapy for adults with Niemann-Pick disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acid Sphingomyelinase Deficiency
• Niemann-pick Disease

Drugs mentioned

• rhASM Enzyme Replacement Therapy (recombinant human acid sphingomyelinase)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Acid Sphingomyelinase Deficiency, Niemann-Pick Disease | Phase 1 | Status: TERMINATED